ArticleAmerican journal of cancer research2026
Actin-related protein 2/3 complex subunit 1B promotes cervical cancer cell tumorigenesis in vitro and in vivo.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) is a major cause of cancer-related mortality in women, with limited therapeutic options for advanced-stage disease. Although Actin-related protein 2/3 complex subunit 1B (ARPC1B) has been shown to play a role in multiple tumours, it is not yet well understood in cervical cancer. Our study has demonstrated that ARPC1B is an important contributor in CC progression. Bioinformatic analysis and tissue microarray (TMA) results revealed that ARPC1B is much more expressed in human cervical carcinoma tissues and positively correlates with poor prognosis. Through a series of in vitro and in vivo functional assays, we showed that ARPC1B plays a decisive role in the proliferation, migration and invasion of cervical cancer cells. Specifically, ARPC1B knockout suppresses the aforementioned malignant phenotypes, whereas its overexpression enhances them. We also proved that ARPC1B promotes tumorigenesis in xenograft models. These findings collectively establish ARPC1B as a novel oncogene in cervical cancer, indicating its potential role as both a biological prognostic marker and a therapeutic target for patients with cervical cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.